Multicenter Phase II Trial of Temsirolimus (TEM) and Bevacizumab (BEV) in Pancreatic Neuroendocrine Tumor (PNET).

Journal of Clinical Oncology - United States
doi 10.1200/jco.2012.30.4_suppl.260
Full Text
Abstract

Available in full text

Date
Authors
Publisher

American Society of Clinical Oncology (ASCO)

Related search

From Parenchymal Preservation to Multiorgan Resection in Pancreatic Neuroendocrine Tumors (pNET), a Tailored Resection Based in Tumor Biology

HPB
HepatologyGastroenterology
2016English

Could Radical Antegrade Modular Pancreatosplenectomy (RAMPS) Be Indicated in Pancreatic Neuroendocrine Tumors (pNET)?

HPB
HepatologyGastroenterology
2016English

Phase I Trial of Sunitinib and Temsirolimus in Metastatic Renal Cell Carcinoma

Clinical Genitourinary Cancer
OncologyUrology
2015English

Gastric Gastrointestinal Stromal Tumor and Neuroendocrine Pancreatic Tumor: Always Neurofibromatosis?

Endoscopic Ultrasound
HepatologyNuclear MedicineRadiologyImagingGastroenterology
2014English

A Randomised Phase II Trial of Selumetinib vs Selumetinib Plus Temsirolimus for Soft-Tissue Sarcomas

British Journal of Cancer
Cancer ResearchOncology
2015English

Phase I Clinical Trial of Temsirolimus and Perifosine for Recurrent Glioblastoma

Annals of Clinical and Translational Neurology
NeuroscienceNeurology
2020English

Bevacizumab Combined With Gemcitabine and Capecitabine for Advanced Pancreatic Cancer: A Phase II Study

British Journal of Cancer
Cancer ResearchOncology
2009English

Phase II Randomized Trial of Sequential or Concurrent FOLFOXIRI‐Bevacizumab Versus FOLFOX‐Bevacizumab for Metastatic Colorectal Cancer (STEAM)

Oncologist
Cancer ResearchMedicineOncology
2019English

Phase II Trial of Gemcitabine and Tanespimycin (17AAG) in Metastatic Pancreatic Cancer: A Mayo Clinic Phase II Consortium Study

Investigational New Drugs
OncologyPharmacology
2015English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy